Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

NCT07243626 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University